


Rev. Add3
Rev. Add5

Schema



Accrual Goal: 846 patients
Cycle = 3 weeks (21 days)

1. Repeat until progression or maximum of 2 years. If maximum treatment duration is reached prior to PD, or treatment is discontinued for any other reason, patient will remain in observation until progression. If patient doesn't continue onto 2nd line treatment, they will proceed to long-term follow-up.
2. Repeat for a maximum of 4 cycles or until disease progression. After cycle 4, pemetrexed can be given alone as maintenance until disease progression or unacceptable toxicity per standard of care.
3. Repeat for a maximum of 4 cycles or until disease progression. After cycle 4, pembrolizumab (MK-3475) and pemetrexed should be given as maintenance until disease progression or two years of treatment for pembrolizumab (MK-3475) in total across 1st and 2nd line treatment. Thereafter, if disease progression is not seen after 2 years, pemetrexed alone may continue until progression per standard of care.
4. Repeat for a maximum of 4 cycles then proceed to maintenance regimen. If disease progression occurs prior to the completion of 4 cycles, patient should instead enter long-term follow-up and continue to their 2nd line treatment off-study, per standard of care.
5. Repeat for 2 years of total treatment across induction and maintenance, or until disease progression. If after 2 years there is no progression, Pemetrexed will continue to be given as maintenance until disease progression per standard of care.
6. Patient enters long-term follow-up and receives 2nd line treatment off-study, per standard of care.
7. Following completion of 2nd line treatment, patient will proceed to long-term follow-up.